368424-95-7Relevant articles and documents
THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
-
Page/Page column 257; 258, (2016/01/25)
The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Papuamides A-D, HIV-inhibitory and cytotoxic depsipeptides from the sponges Theonella mirabilis and Theonella swinhoei collected in Papua New Guinea
Ford, Paul W.,Gustafson, Kirk R.,McKee, Tawnya C.,Shigematsu, Nobuharu,Maurizi, Laura K.,Pannell, Lewis K.,Williams, David E.,De Silva, E. Dilip,Lassota, Peter,Allen, Theresa M.,Van Soest, Rob,Andersen, Raymond J.,Boyd, Michael R.
, p. 5899 - 5909 (2007/10/03)
The novel cyclic depsipeptides papuamides A (1), B (2), C (3), and D (4) have been isolated from Papua New Guinea collections of the sponges Theonella mirabilis and Theonella swinhoei. Their structures were determined by a combination of spectroscopic analysis and chemical degradation and derivatization studies. In addition to glycine, alanine, and threonine, these peptides contain a number of unusual amino acids including 3,4- dimethylglutamine, β-methoxytyrosine, 3-methoxyalanine, and 2,3- diaminobutanoic acid or 2-amino-2-butenoic acid residues. Papuamides A-D (1- 4) are also the first marine-derived peptides reported to contain 3- hydroxyleucine and homoproline residues. These peptides also contain a previously undescribed 2,3-dihydroxy-2,6,8-trimethyldeca-(4Z,6E)-dienoic acid moiety N-linked to a terminal glycine residue. Papuamides A (1) and B (2) inhibited the infection of human T-lymphoblastoid cells by HIV-1(RF) in vitro with an EC50 of approximately 4 ng/mL. Compound 1 was also cytotoxic against a panel of human cancer cell lines with a mean IC50 of 75 ng/mL.